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Abstract
Resistance mutations to the HIV-1 fusion inhibitor enfuvirtide emerge mainly within the drug’s target region, HR1, and
compensatory mutations have been described within HR2. The surrounding envelope (env) genetic context might also
contribute to resistance, although to what extent and through which determinants remains elusive. To quantify the direct
role of the env context in resistance to enfuvirtide and in viral infectivity, we compared enfuvirtide susceptibility and
infectivity of recombinant viral pairs harboring the HR1–HR2 region or the full Env ectodomain of longitudinal env clones
from 5 heavily treated patients failing enfuvirtide therapy. Prior to enfuvirtide treatment onset, no env carried known
resistance mutations and full Env viruses were on average less susceptible than HR1–HR2 recombinants. All escape clones
carried at least one of G36D, V38A, N42D and/or N43D/S in HR1, and accordingly, resistance increased 11- to 2800-fold
relative to baseline. Resistance of full Env recombinant viruses was similar to resistance of their HR1–HR2 counterpart,
indicating that HR1 and HR2 are the main contributors to resistance. Strictly X4 viruses were more resistant than strictly R5
viruses, while dual-tropic Envs featured similar resistance levels irrespective of the coreceptor expressed by the cell line
used. Full Env recombinants from all patients gained infectivity under prolonged drug pressure; for HR1–HR2 viruses,
infectivity remained steady for 3/5 patients, while for 2/5 patients, gains in infectivity paralleled those of the corresponding
full Env recombinants, indicating that the env genetic context accounts mainly for infectivity adjustments. Phylogenetic
analyses revealed that quasispecies selection is a step-wise process where selection of enfuvirtide resistance is a dominant
factor early during therapy, while increased infectivity is the prominent driver under prolonged therapy.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) envelope
glycoprotein (Env) mediates viral entry into the host cell by fusion of
the viral envelope with the host cell membrane (reviewed in [1,2,3]).
The Env complex is composed of two non-covalently linked
subunits, the surface glycoprotein (gp120) and the transmembrane
glycoprotein (gp41), displayed as homotrimers at the surface of the
virion and of infected cells. Viral entry is a multistep phenomenon:
Binding of gp120 to the CD4 receptor expressed on the surface of
target cells induces a conformational change that exposes the third
hypervariable loop (V3) of gp120, which in turn binds one of the two
chemokine receptors CCR5 (R5 viruses) or CXCR4 (X4 viruses).
Consequently, the viral V3 sequence defines cell tropism to a large
extent, although regions outside the V3-loop have been described to
modulate coreceptor usage [4,5,6]. Coreceptor binding triggers
further conformational changes in the ectodomain of gp41 that lead
to the insertion of the N-terminal glycine-rich fusion peptide into the
host cell membrane. Folding of heptad repeat 2 (HR2) region onto
heptad repeat 1 (HR1) region forms a highly stable six helix bundle
structure and brings the viral and host cell membranes into close
contact, ultimately leading to the fusion of both membranes
[7,8,9,10].
It has been shown that synthetic peptides that bind to one of the
HR motifs interfere with the formation of a stable six helix bundle
and inhibit viral entry [7,11,12,13]. Enfuvirtide (ENF, T-20)
[11,14] is a subcutaneously injected 36 amino acids (AA) peptide
mimicking part of the HR2 sequence (AA 127 to 162). Enfuvirtide
binds HR1 and hinders the fusion process by preventing the HR1–
HR2 interaction. Enfuvirtide is active against multi-drug resistant
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viral strains and is currently recommended as salvage therapy for
highly drug experienced patients.
Enfuvirtide resistant HIV-1 variants however rapidly emerge
under enfuvirtide selective pressure [15,16] and resistance muta-
ftions have been described both in vitro and in vivo [17,18,19,
20,21,22,23,24,25,26,27]. Most resistance mutations are located
within HR1, between AA 36 and 45 (HXB2 numbering)
[17,18,25]. Some resistance mutations, reduce viral infectivity in
the absence of the drug, probably as a consequence of impaired
interactions between HR1 and HR2 and delayed fusion kinetics
[19,28,29,30]. Compensatory mutations that restore viral infec-
tivity may arise within HR2 [19,26,29,31]. Some of these
mutations, such as the S138A substitution, have been suggested
to confer some resistance per se [19,29], but others do not or only
modestly impact the level of resistance.
Enfuvirtide operates by a unique mechanism as it does not
target the static Env, but a structural intermediate of the entry
process, called the fusogenic intermediate, induced by binding of
gp120 to the CD4 receptor. Hence, factors that influence the short
kinetic window during which HR1 is accessible to the peptide also
influence viral susceptibility. Env determinants outside of HR1
and HR2, including tropism, coreceptor affinity [30,32,33], the
CD4 binding region of gp120 [20] and the bridging sheet region
[30], have been shown to modulate the level of susceptibility/
resistance to enfuvirtide. Although the impact of coreceptor usage
on the level of susceptibility has been addressed by many authors,
results remain controversial, likely a consequence of different
experimental and analytical approaches [27,32].
Furthermore, it has been suggested that other determinants
outside of HR1 may be involved in resistance and/or that the env
genetic context drives the selection of Envs in which resistance
mutations emerge [34,35,36]. The present study addresses the
relative contributions of Env determinants outside of the HR1 and
HR2 regions to resistance to enfuvirtide and to viral infectivity by
comparing NL4-3-derived recombinant virus pairs harboring either
the sole HR1–HR2 region or the entire Env (gp120+gp41)
ectodomain from longitudinal HIV-1 Envs cloned from plasma
from 5 heavily treated patients receiving enfuvirtide as part of a
salvage regimen. Our results indicate that (i) the HR1–HR2 region
is the major contributor to resistance, while the env genetic
background modulates baseline susceptibility and to a lesser extent
resistance after virological failure, (ii) coreceptor usage, and
particularly strict X4 tropism, was associated with higher resistance
(iii) the env genetic context contributes to restoring viral infectivity,
and (iv) both the level of resistance and viral infectivity orchestrate
the selection of variants under prolonged enfuvirtide pressure.
Results
Generation of HR1–HR2 and full Env recombinant viral
particles
Eighty full envelopes were cloned. All the tested HR1–HR2
recombinant viruses were infectious, but only 65% (52/80) of the
full Env recombinant viruses were infectious, in line with previous
reports [35]. A higher proportion (77.3%, 17/22) of baseline clones
were infectious compared to enfuvirtide-escape clones (60.3%, 35/
58) and very few late clones were infectious (Table S1). Phenotypic
analyses were restricted to clones that allowed to generate both
HR1–HR2 and full Env infectious recombinant viruses (n= 52).
Baseline genotypic and phenotypic susceptibility to
enfuvirtide
No known enfuvirtide resistance mutation was detected in pre-
treatment clones. Viruses from patients A, C, D and E carried the
subtype B HR1 consensus sequence GIVQQQNNLL between
AA 36 and 45. All the pre-treatment viral env clones from patient B
carried the N42S polymorphism (Table S1).
Full Env recombinant viruses displayed greater variability in
enfuvirtide susceptibility (FCIC50 range: 0.91–27.47) than HR1–
HR2 recombinant viruses (FCIC50 range: 0.47–7.16) (Fig. 1.A).
Overall median FCIC50 of the full Env recombinant viruses was
higher than that of the HR1–HR2 recombinant viruses (Fig. 1.A)
(p=0.05), indicating that the env genetic context lowered
susceptibility to enfuvirtide. At a single clone level, all the full
Env pre-treatment recombinant viruses from patients A, C, D and
E were less susceptible than the corresponding HR1–HR2
recombinant viruses (Fig. 1.A and Fig. 2.A, C, D and E, Table S1).
In contrast, patient B pre-treatment HR1–HR2 recombinant
viruses displayed higher FCIC50 than their full Env counterparts
(Fig. 1.A). When compared to the 4 other patients’ envs, full Env
recombinant viruses from patient B were more susceptible to
enfuvirtide than those from the 4 other patients (p=0.02), while
HR1–HR2 recombinant viruses were less susceptible than those of
the 4 other patients (p=0.01) (Fig. 1.B).
Genotypic and phenotypic resistance during enfuvirtide
treatment
All the clones retrieved from patients after enfuvirtide treatment
failure harbored at least one known resistance mutation within
HR1, at positions 36 and/or 38 (patients A and C) and at positions
42 and/or 43 (patients B, D and E) (Table S1). Of note, none of
the clones carried resistance mutations concomitantly at positions
36 and 38, 36 and 43 or 38 and 43, in contrast to reports by others
[34,35]. FCIC50 of escape recombinant viruses increased 11- to
2800-fold relative to baseline. Overall, median FCIC50 of full Env
recombinant viruses did not differ significantly from the FCIC50 of
HR1–HR2 recombinant viruses (full Env median FCIC50 = 1469
[177;2401], HR1–HR2 median FCIC50 = 1062 [481;1877],
p.0.05). Likewise, at an individual patient level, no significant
difference was detected in the level of resistance between full Env
and HR1–HR2 recombinant viruses (patients A, B, D and E).
For 3 patients, resistance was associated with mutations at one
position at all time points (AA 36 for patient A, AA 43 for patients
B and E) and featured an over 100-fold increase in FCIC50 relative
to the corresponding baseline clones, regardless of coreceptor
usage (Fig. 2.A, B and E, Table S1). For patient B, FCIC50s of the
HR1–HR2 recombinant viruses were higher than those of the
corresponding full Env recombinant viruses at weeks 16 and 45, as
for baseline clones. Furthermore, the level of resistance of HR1–
HR2 recombinant viruses remained steady between weeks 16 and
45, whereas full Env recombinant viruses reached 3-fold higher
resistance levels at week 45 than at week 16 (Fig. 2.B, Table S1),
highlighting that the env genetic context did not easily tolerate the
constraints that allowed escaping enfuvirtide treatment. Because of
the limited availability of early and late clones for patients A and
E, variations in the level of resistance over time could not be
assessed.
For patients C and D, resistance was associated with multiple
mutations evolving over time. For patient C, 4/5 early escape
viruses carried the G36D substitution and one clone carried the
V38A mutation. The V38A variant featured 4-fold (full Env) and
6-fold (HR1–HR2) higher resistance than the early G36D clones
(Fig. 2.C, Table S1). At later time points, only the V38A mutation
was detected associated with the L44M resistance mutation.
Resistance of intermediate and late clones increased by 15-fold at
week 59, and by 40-fold (HR1–HR2 recombinants) and 24-fold
(full Env recombinants) at week 129 (p=0.03). For patient D, 3/5
early env clones carried the N43D resistance mutation and one
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infectious clone carried the N42D+N43S mutations (Fig. 2.D,
Table S1). The N43D mutants were 2 to 6-fold more resistant than
the N42D+N43S double mutant for both HR1–HR2 and full Env
recombinants (Fig. 2.D, Table S1). All intermediate and late Env
clones (weeks 59 and 94) carried the N43D mutation with the
N126K substitution [37], although in contrast to patient C,
phenotypic resistance levels did not increase further under
prolonged treatment (Fig. 2.D and Table S1). These observations
suggest that the higher level of resistance conferred by the V38A or
the N43D mutations drove the selection of Envs between early and
intermediate/late time points.
Altogether, HR1–HR2 contains the main determinants of
resistance, irrespective of the resistance mutations that were
selected, while other env-encoded determinants outside of HR1–
HR2 modulate the level of resistance to a marginal extent,
probably by driving the selection process of viral Envs with
increased resistance under drug pressure.
Impact of tropism on the level of resistance
Because tropism has been described to modulate susceptibility to
enfuvirtide [27,32], we compared resistance of strictly X4, strictly
R5 and dual tropic clones. X4 Env recombinant viruses tended to
be more resistant than R5 recombinant viruses at baseline and after
virological failure (2.7-fold) (X4 median FCIC50= 2499 [2273;
4464], R5 median FCIC50= 924 [284;1714]) (p=0.001). For dual-
tropic viruses, resistance was found to be similar, irrespective of the
coreceptor expressed by the cell line used (data not shown).
Relative viral infectivity during enfuvirtide treatment
We then investigated whether the env genetic context surround-
ing HR1–HR2 played a role in infectivity adjustments. Overall,
HR1–HR2 recombinant viruses featured higher median relative
infectivities (RI) than their full Env counterparts prior to and after
enfuvirtide treatment escape: pre-treatment median HR1–HR2
RI= 0.89 [0.58;1.22] vs median Env RI= 0.16 [0.04;0.43],
(p=0.006) and after treatment failure median HR1–HR2
RI= 0.67 [0.44;1.21] vs median Env RI= 0.28 [0.13;0.75],
p=0.01. Because in this in vitro system differences in infectivity
between paired recombinant viruses probably reflect the higher
infectivity of HXB2-derived gp120 of HR1–HR2 recombinants
over patient-derived primary gp120 of full env recombinants, we
compared the changes in RI of HR1–HR2 and of full Env
recombinant viruses during the time of follow-up rather than
HR1–HR2/full Env recombinant virus pairs at a given time point.
RIs of full Env recombinant viruses spanned a wider range than
RIs of HR1–HR2 recombinant viruses, consistent with the high
genotypic conservation of the HR1–HR2 region. Early after
enfuvirtide failure, RI of the escape variants was similar to or lower
than at baseline for both HR1–HR2 and full Env recombinant
viruses (Fig. 3). At later time points (intermediate and late), RI of
full Env recombinant viruses increased for all patients relative to
early escape clones (Fig. 3). The RI of HR1–HR2 recombinant
viruses, by contrast, remained steady for patients A, B and E,
strongly indicating that determinants other than HR1–HR2
account for infectivity adjustments, either through the emergence
of compensatory mutations or through the selection of Envs that
best tolerate resistance mutations. For patients C and D, in
contrast, HR1–HR2 recombinant viruses showed a trend to
increase, likely mapping determinants that account for gains in
infectivity to HR1–HR2.
Among the polymorphisms previously described to modulate
viral infectivity, compensatory mutation S138A [19] was detected
in 5/9 escape Envs from patient B, in 9/10 intermediate and late
escape Envs from patient D (but in none of the early escape Envs)
and in all viral escape clones from patient E (Table S1). In all
patients, however, the RIs of variants carrying the S138A
mutation were comparable to those of variants carrying wild-type
S138 (Fig. 3 and Table S1), suggestive that the relative
Figure 1. Baseline fold changes in enfuvirtide IC50 (FCIC50) of the full Env and HR1–HR2 recombinant viruses from patients A
(green), patient B (pink), patient C (red), patient D (blue) and patient E (brown) determined on U87.CD4 cells expressing either
CCR5 or CXCR4. Medians with interquartile ranges are reported at the top of the graphs. Panel A: Pairwise comparison of full Env FCIC50 and HR1–
HR2 FCIC50 for each patient. Panel B: FCIC50 of the HR1–HR2 (column 1) and full Env recombinant viruses (column 3) from patient B compared to the
HR1–HR2 (column 2) and full Env recombinant viruses (column 4) from all other patients. HR1–HR2 viruses are represented as closed triangles (m). For
full Env recombinant viruses, closed circles (N) represent strictly X4 viruses, open circles (#) represent dual-tropic clones tested on CXCR4-expressing
cells, closed squares (&) represent strictly R5 viruses and open squares (%) represent dual-tropic clones tested on CCR5-expressing cells.
doi:10.1371/journal.pone.0021535.g001
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contribution of the S138A substitution to infectivity rescue might
also involve other determinants. Other mutations included
substitutions N125D [29,38] (patients A, B and C), N125S and
N126K [37,39,40] (patient D) and E137K [41,42] (patient E)
(Table S1). The N125D/S polymorphisms within HR2 were
detected in both baseline and escape clones, arguing against them
playing a pivotal role in restoring infectivity. For patient E, the
impact of E137K is difficult to evaluate as only intermediate clones
were recovered and as gains in viral infectivity seem to map to env
determinants outside of HR1–HR2 (Fig. 3.E). In contrast, the
N126K compensatory mutation in patient D viruses was detected
exclusively in on-treatment viral sequences, pointing to it as a
presumed contributor to the parallel infectivity gains of HR1–
HR2 and full Env recombinants. Taken together, our data suggest
that both compensatory mutations within HR1–HR2 (N126K for
patient D, yet unidentified determinants for patient C) and the env
genetic context (patients A, B and E) contribute to increased viral
infectivity.
Phylogenetic analysis of full env sequences
Phylogenetic analyses were performed to dissect the relative
contributions of resistance and of infectivity to selective evolution
under prolonged enfuvirtide pressure.
For patients A and B, all the clones (baseline and post-treatment
failure) were intermingled, suggesting that these viral populations
explored different evolutionary routes. Early resistance mutations
(G36D and N42S+N43D) conferred high level resistance (.100-
fold) and persisted throughout treatment (Fig. 4.A and B). For
patient B, week 45 clones grouped on one branch and were related
to pre-treatment clone 25.16 and early clone 16.1. The gain in
infectivity of intermediate clones relative to the early clones was
higher than the gain in resistance, suggesting that the evolutionary
paths embraced must have favored infectivity adjustments.
For patients C and D, viral clones from each time point
clustered together. Both patients hosted strains with resistance
mutations at 2 positions at early time points (Table S1), and
determinants within HR1–HR2 were sufficient to confer enfuvir-
tide resistance and to restore viral infectivity. The V38A (patient
C) and N43D (patient D) mutations conferred higher resistance
than the G36D (patient C) or N42D+N43S (patient D) mutations
respectively, and at intermediate and late time points, the early
G36D and N42D+N43S variants were outcompeted by V38A or
the N43D variants (Fig. 2 and Fig. 3), indicating that early after
treatment escape, the level of resistance is the main driver of viral
selection.
It is noteworthy that for patients A and D, only one late clone
was infectious. For patient C, all late (week 129) clones were
extremely tightly related and emerged from the branch grouping
early G36D variants (clones 27.3, 27.4, 27.6) rather than from the
early V38A variant or from the intermediate V38A+L45M
variants (Fig. 4.C). For these 3 patients, late infectious clones
stemmed from early rather than from intermediate escape clones,
suggesting that the other evolutionary viable paths explored by the
virus at the intermediate time point, led to a dead-end under
pursued enfuvirtide pressure (Fig. 4.A, C and D). Late infectious
clones had similar resistance levels than early/intermediate clones
and high RIs (Fig. 2 and Fig. 3), indicating that infectivity levels
molded selection at late time points.
These findings highlight restricted evolution and limited
evolutionary possibilities under prolonged enfuvirtide pressure,
and illustrate that while resistance may be achieved through
different paths, optimal Env properties enhancing RI are highly
constrained.
Discussion
In this study, direct comparison of HR1–HR2 and full Env
recombinant viral particles containing longitudinal Envs from 5
patients receiving prolonged enfuvirtide-based therapy, formally
points to HR1 and HR2 as the principal contributors to high level
resistance. The surrounding env genetic context played a
modulatory role on basal susceptibility and to a lesser extent on
the level of resistance, in line with a previous report [16]. Previous
studies have suggested that the env genetic context contributes to
resistance to enfuvirtide both directly and by driving the selection
of resistance mutations [23,34,35]. In these reports, escape
variants that appeared under enfuvirtide pressure evolved from
minority variants present prior to treatment. Because the selected
resistance mutations conferred higher resistance levels within the
genetic context within which they arose than in pre-therapeutic env
clones from the same patient, the authors conclude that the env
genetic context drives the resistance pathway embraced by viruses
under drug pressure and that the level of resistance is the primary
determinant of selection [34,35]. These reports contrast with the
mainly modulatory role of the env genetic context we recorded. In
our study, the weight of the full Env ectodomain was compared to
isogenic HR1–HR2, while in the study by Goubard et al. [35] one
single mutation (V38A) was inserted by site-directed mutagenesis.
It is therefore not possible to exclude that in their study, the HR1–
HR2 region rather than the full Env accounted for the env-encoded
contribution to enfuvirtide resistance.
In the case of patient B, the env genetic context lowered the level
of resistance. Furthermore, the HR1–HR2 recombinant viruses
from this patient were less susceptible to enfuvirtide than the
HR1–HR2 recombinants from the other patients despite the
N42S polymorphism, which has been associated with increased
enfuvirtide susceptibility and a slightly improved virological
outcome [25,27,43]. In this patient, other yet undetermined, env-
encoded determinants likely contributed to the particularly high
susceptibility to enfuvirtide, and/or the env genetic context
remained essentially unfavorable to the development of enfuvirtide
resistance. Noteworthingly, patient B hosted only strictly R5
viruses. It is therefore possible that tropism was one of the
determinants that contributed to render full Env recombinants less
susceptibile to enfuvirtide than the isogenic HR1–HR2 recombi-
nants.
We show that X4-coreceptor usage was the only factor
associated with significantly lower resistance levels. Coreceptor
usage has been previously reported to influence susceptibility/
resistance to enfuvirtide, but contradictory results have been
reported depending on the design of the study and on whether
Figure 2. Phenotypic enfuvirtide resistance of full Env and HR1–HR2 recombinant viruses. U87.CD4.CCR5 and U87.CD4.CXCR4 were
infected with HR1–HR2 and full Env recombinant viruses in the presence of decreasing concentrations of enfuvirtide, ranging from 156103 ng/ml to
0.04 ng/ml). Resistance is expressed as fold changes in IC50 (FCIC50) normalized to the HXB2 reference. For full Env recombinant viruses, resistance
was determined on U87.CD4 cells expressing either CCR5 (red) or CXCR4 (blue). Closed circles (N) represent strictly R5 or X4 recombinant viruses and
open circles (#) represent dual-tropic recombinant viruses. FCIC50 of HR1–HR2 recombinant viruses are represented as closed triangles (m) and were
tested on U87.CD.CXCR4 cells. Medians (horizontal bars) of at least two independent experiments are shown. Medians with interquartile ranges are
reported at the top of the graphs.
doi:10.1371/journal.pone.0021535.g002
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Figure 3. Relative infectivity (RI) of full Env and HR1–HR2 recombinant viruses. U87.CD4.CCR5 and U87.CD4.CXCR4 were infected with
serial two-fold dilutions (ranging from 400 pg p24/well to 50 pg p24/well) of HR1–HR2 and full Env recombinant viruses. Luciferase activity was
monitored as a function of p24 input to assess infectivity and was normalized to the HXB2 reference to estimate RI. For full Env recombinant viruses,
RI was determined on U87.CD4 cells expressing either CCR5 (red) or CXCR4 (blue). Closed circles (N) represent strictly R5 or X4 recombinant viruses
and open circles (#) represent dual-tropic recombinant viruses. RI of HR1–HR2 recombinant viruses are represented as closed triangles (m) and were
Impact of env on T20 Resistance and Infectivity
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dual/mixed viruses are considered separately or included among
the X4 strains [27,32,33,36]. Here we constructed env recombinant
clones and analyzed strictly R5, strictly X4 and dual-tropic viruses
as 3 distinct groups. The lower susceptibility of X4 recombinant
viruses at baseline and after virological failure may reflect other
intrinsic properties of gp120 [30,44,45]. Formal quantification of
the gain in resistance associated with X4 tropism would require
switching tropism by site-directed mutagenesis. In our study, X4
tested on U87.CD.CXCR4 cells. Medians (horizontal bars) of at least two independent experiments are shown. Medians with interquartile ranges are
reported at the top of the graphs.
doi:10.1371/journal.pone.0021535.g003
Figure 4. Phylogenetic analysis of the full env sequences. Complete env coding sequences were aligned with HXB2 as the outgroup using the
MUSCLE software and phylogenetic trees were constructed using the PhyML software. Main resistance mutations and compensatory mutations are
indicated for each clone. Non-infectious clones are marked with a *. Bootstrap values .60% are indicated.
doi:10.1371/journal.pone.0021535.g004
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recombinant viruses (both full Env X4 and HR1–HR2 viruses)
also featured higher infectivity than R5 recombinants. Although
the design of our experimental system is not suited to study the
potential relationship between the level of resistance and
infectivity, it is plausible that the lower susceptibility of X4
recombinant viruses is related to properties of gp120 that
accelerate the fusion process, such as fusion kinetics, coreceptor
affinity and binding sites [30,44,45]. Yet, the fact that dual tropic
full Env recombinant viruses displayed similar FCIC50 in both the
CXCR4- and CCR5-cell lines irrespective of infectivity levels in
each cell type, argues against a direct relation between viral
infectivity and enfuvirtide susceptibility. Alternatively, dual tropic
viruses might differ from strictly R5 or strictly X4 viruses through
intermediate fusion kinetics, in line with their intermediate median
FCIC50 (data not shown).
Previous studies have reported both decreases and increases in
viral infectivity under enfuvirtide treatment [28,34]. We did not
detect pronounced reductions in viral infectivity (for both HR1–
HR2 and full Env recombinant viruses), as reported by others
[23]. However, working with clones implicitly restrains phenotypic
analyses to infectious clones only, and we cannot exclude that
losses in viral infectivity might be underestimated. Indeed, 77.3%
of the baseline clones but only 60.3% of the escape clones were
infectious, especially very few late clones were infectious. We
found that both determinants within the HR1–HR2 regions
(including compensatory mutations such as the S138A, N125D or
N126K) and other gp120 properties likely accounted for gains in
viral infectivity.
All patients achieved high level resistance as of the earliest time
points and different resistance pathways were attempted. Early
escape clones (patients C and D) with lower resistance were
outcompeted by more resistant clones carrying the V38A or N43D
resistance mutations respectively, indicating that the level of
resistance reached is indeed one major determinant of evolution,
as previously suggested [15,23,35]. Nonetheless, we found that
intermediate and late infectious clones from all patients progres-
sively gained RI revealing that viral infectivity also strongly molds
the selection of escape variants, and becomes the prevalent actor of
evolutionary adjustments under prolonged drug pressure once
high level resistance is established. These apparently discrepant
results with previous reports that attribute the selection of viral
strains under sustained enfuvirtide pressure to the sole level of
resistance [23,35] might be due to the duration of enfuvirtide
pressure: the latest on-therapy samples in the studies by Menzo et
al. and by Goubard et al. were retrieved after 20 and 37 weeks of
treatment, corresponding to a time-point between early and
intermediate in our study. At these time-points, the level of
resistance is indeed probably the major determinant of quasis-
pecies selection, and viral diversity is still preserved. However, at
later time points it is the level of infectivity that drives the selection
of particular Envs, a process that is highly constrained and strikes
genetic diversity.
In conclusion, our findings indicate that selection of viral variants
is molded gradually by the level of resistance achieved through
mutations within HR1–HR2 at first, and by the viral determinants
mining viral infectivity, including specific compensatory mutations
and polymorphisms as well as other Env properties. The first step of
the process, escaping enfuvirtide pressure and achieving resistance,
can occur via different routes and involve a diversity of mutations, as
illustrated by the relative dispersal of early escape clones from all
patients throughout the phylogenetic trees. Infectivity adjustments
occur later and are likely more strongly constrained by the env
genetic context, translating into evolutionary ‘‘turn-backs’’ and
scarse phylogenetic diversity.
Materials and Methods
Patients and patient samples
Patients belong to the Dutch ATHENA Cohort for treatment
evaluation and the study received ethical approval in the
Netherlands. HIV-infected patients are informed that their data/
samples are collected as part of the ATHENA evaluation study
and consent is arranged according to an opting out procedure.
Clinicians sign a form to assign patients to the Cohort.
Five heavily treated male patients receiving enfuvirtide (90 mg
twice daily) (Roche Pharmaceuticals) as part of a salvage regimen
in addition to an optimized background treatment (OBT) and who
experienced virological failure were selected. All patients were
infected with subtype B viruses. Median viral load was 125372
RNA copies/ml (range: 4960–372000) and mean CD4+ cell counts
were 147 cells/ml (range: 30–410) at baseline (Table S2). A median
of 10 (range: 9–12) resistance mutations to reverse transcriptase
inhibitors and a median of 10 (range: 6–12) resistance mutations to
protease inhibitors were detected. Enfuvirtide treatment initiation
induced a decrease from 0.8 log to 3.0 log HIV-RNA. All patients
experienced virological failure after a median of 20 weeks on
enfuvirtide+OBT. Patient B interrupted ENF therapy between
weeks 22 and 29. Longitudinal frozen plasma samples prior to
enfuvirtide treatment (baseline) and longitudinal samples during
treatment failure were selected.
Cell lines
HEK293T (ATCC) cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10%
heat-inactivated foetal bovine serum (FBS), L-glutamine (2 mM),
penicillin (50 U/mL) and streptomycine (50 mg/mL) (all from
Gibco). U87.CD4.CCR5 and U87.CD4.CXCR4 cells (AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH [46]) were maintained in DMEM supplemented
with 15% FBS, L-glutamine (2 mM), penicillin (100 U/mL),
streptomycine (100 mg/mL), geneticine (300 ng/mL) (Gibco) and
puromycine (1 ng/mL) (Sigma-Aldrich). Expression of CD4,
CCR5 and CXCR4 was monitored by flow cytometry.
Cloning and analysis of patient-derived full envs
HIV-1 RNA was isolated as previously described [47]. env was
reverse transcribed and amplified using forward primer Env1a
(59-GGCTTAGGCATCTCCTATGGCAGGAAGAA-39 HXB2
5954-5982) and reverse primer Env1b (59-TAGCCCTTCCA-
GTCCCCCCTTTTCTTTTA-39 HXB2 9096-9068) for pa-
tient C (baseline, early and intermediate) and forward prim-
er FLenv1.1 (59-TAGAGCCCTGGAAGCATCCAGGAAG-39
HXB2 5853-5877) and reverse primer FLenv1.2 (59-TTGC-
TACTTGTGATTGCTCCATGT-39 HXB2 8936-8913) for all
other samples The RT-PCR mix contained. 4.8 ml viral RNA,
0.2 mM of each primer, 0,4 mM of each dNTP (GE Health-
Care), 3.3 mM MgSO4, 0.5 ml SuperScript III RT/Platinum
Taq High Fidelity DNA polymerase and 8 units RNAseOUT
(Invitrogen Life Sciences), and conditions were as follows: reverse
transcription for 30 min at 55uC, denaturation for 2 min at
94uC, and 30 amplification cycles (94uC for 20 s, 55uC for 30 s,
68uC for 4 min) followed by a final extension at 68uC for
5 minutes. 5 ml of this PCR product were further amplified over
30 cycles (95uC for 15 s, 58uC for 30 s, 68uC for 4 min) using
forward primer Env2a (59-AGAAAGAGCAGAAGACAGTGG-
CAATGA-39) HXB2 6202-6228) and reverse primer Env2b
(59-TTTTGACCACTTGCCACCCAT-39 HXB2 8797-8817)
for patient C (baseline, early and intermediate) and forward
primer FLenv2.1 (59-GATCAAGCTTTAGGCATCTCCTA-
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TGfGCAGGAAGAAG-39 HXB2 nt 5957-5983) and reverse
primer FLenv2.2 (59-AGCTGGATCCGTCTCGAGATACT-
GCTCCCACCC-39 HXB2 8904-8882) for all other samples.
The nested PCR mix contained 2.0 mM MgSO4, 0.3 mM of
each primer, 1.6 units Expand High Fidelity enzyme mix (Roche
Applied Science) and 0,2 mM of each dNTP in Expand High
Fidelity buffer. PCR products were purified (QIAquick PCR
purification kit, Qiagen), A-tailed with 5 units of Taq DNA
polymerase (Roche Applied Biosystems) at 70uC for 20 minutes,
and TA-cloned in the pGEM-T-easy vector (Promega) using T4
DNA ligase (Promega) overnight at 4uC. Five clones were
randomly selected for each time point (Table S1). For data
analysis purposes, clones were classified as ‘‘baseline’’ (pre-enfu-
fvirtide), ‘‘early’’ (first time point after virological failure, weeks
16 to 27), ‘‘intermediate’’ (weeks 42 to 59) and ‘‘late’’ (after week
94). For patients A and D, only one late clone was infectious and
was therefore grouped with the corresponding intermediate
clones.
All clones were sequenced (Genbank accession numbers
HQ386140 to HQ386219). Full clonal env sequences were aligned
against HXB2 using the MUSCLE software (v3.8.31) [48].
Amplification of patient-derived env and HR1–HR2
sequences
env and HR1–HR2 fragments were PCR amplified from single
clones and from reference pHXB2-env (AIDS Research and
Reference Reagent Program, NIH) [49] using forward primer
FLenv2.11. (59-GCTTAGGCATCTCCTATGGCAGGAAGAA-
G-39 HXB2 5955-5983) and reverse primer rec.env_RP (59-
AAGCCCTGTCTTATTCTTCTAGGTATGT-39 HXB2 8776-
8749) for the env amplicon, and forward primer rec.HR1-2_FP (59-
GAGGGACAATTGGAGAAGTGAAT-39 HXB2 7649-7671)
and reverse primer rec.HR1-2_RP (59-GGTGAATATCCCTG-
CCTAACTC-39 HXB2 8365-8344) for the HR1–HR2 amplicon.
Clonal template DNA was amplified using 1.5 units Platinum Taq
High Fidelity DNA polymerase (Invitrogen Life Sciences) in High
Fidelity Platinum PCR buffer containing 1,5 mM MgSO4,
0,2 mM of each dNTP, 0,2 mM of each primer over 35 cycles
(94uC for 30 s, 64uC for 30 s, 68uC for 3 min (env)/1 min (HR1–
HR2)) followed by a final extension at 68uC for 10 minutes. DNA
concentration and quality were assessed by gel electrophoresis and
triplicate DNA amplifications were pooled.
Phylogenetic analyses
Phylogenetic analyses of env sequences were performed using the
Maximum Likelihood method [50,51] and the gamma corrected
HKY85 [52] model of molecular evolution as suggested by the
TOPALi software package (v2.5), setting HXB2 as the outgroup.
Bootstrap values were determined using 1000 replicates.
Production of Env and HR1–HR2 recombinant viruses
The EcoRI-NotI fragment from the previously described pNL4-
3.GIV.eGFP [53], was subcloned into pZero-2 (Invitrogen Life
Sciences) to engineer two luciferase-tagged pNL4-3-derived vectors
pNL4-3Denv and pNL4-3DHR1–HR2. To construct pNL4-3Denv,
the env ectodomain was deleted by inverse PCR using the pho-
sphorylated reverse primer del.env_RP (59-GCTGTCTTCTG-
CTCTTTCTATTAG-39, HXB2 6220-6197) and forward primer
del.env_FP (59-GCTGTACTTTCTATAGTGAATAGAGTT-39,
HXB2 8322-8348), creating an AfeI restriction site (shown in italic)
for linearization. The parental DNA fragment was DpnI digested
and the PCR amplicon was self-ligated using T4 DNA ligase (New
England Biolabs) and transformed into electrocompetent TOP10
E.coli cells (Invitrogen Life Sciences). The SalI-BamHI fragment
containing the remaining endodomain of gp41 was then cloned into
the SalI-BamHI digested plasmid pNL4-3.Luc (gift of T. Dragic,
Albert Einstein College of Medicine) [54], generating pNL4-
3Denv.Luc. pNL4-3DHR1–HR2.Luc was engineered similarly, using
the phosphorylated reverse primer del.HR1-2_RP (59-ATTGG-
CGCGCCTGTACCGTCA-39 (HXB2 7854-7834) and forward
primer del.HR1-2_FP (59-GATAAATGGGCAAGTTTGTGG-39
(HXB2 8214-8234) creating an AscI restriction site (shown in italics)
(Fig. S1) for linearization. Correct deletion of the env and of the
HR1–HR2 regions was attested by sequencing.
Full Env andHR1–HR2 recombinant viral particles were generated
by cotransfecting HEK293T cells with 8 mg of AfeI-linearized pNL4-
3Denv.Luc or AscI-linearized pNL4-3DHR1–HR2.Luc with 4 mg of env
amplicon or 1 mg of HR1–HR2 amplicon respectively, packaged in
20 ml of HEKFectine (Bio-Rad). Cell culture medium was harvested
48 hours later and clarified at 4uC to eliminate cell debris, and p24
antigen concentration was quantified by ELISA (Perkin-Elmer).
Experimental biases due to the recombination event with two
different amplicons were excluded by verifying that HR1–HR2
and full Env recombinant viruses produced from HXB2 and from
an otherwise identical HXB2-derived double mutant carrying the
G36S+V38M mutations in gp41 (HXB2-SIM) featured similar
IC50 and infectivity levels (data not shown).
Determination of viral infectivity
104 U87.CD4.CXCR4 or U87.CD4.CCR5 cells seeded in 96-
well plates were infected (in triplicate wells) with serial 2-fold
dilutions of viral supernatants, (400 to 50 pg/well of p24 antigen).
Infection was synchronized by spinoculation (12006g, 2 hours,
25uC) and monitored after 48 hours by measuring biolumines-
cence in cell lysates (Promega luciferase assay system) using a
Tecan Genios Pro Luminometer. Relative Light Units (RLUs)
were plotted against viral p24 inoculi and the slope of the linear
regression was calculated using GraphPad Prism v5.01 (GraphPad
Software). Relative infectivity (RI) was defined as the ratio of the
infectivity (slope) of each recombinant virus to that of the reference
strain HXB2.
Enfuvirtide phenotypic susceptibility/resistance testing
104 U87.CD4.CXCR4 or U87.CD4.CCR5 cells were infected
with recombinant viral supernatants in the presence of increasing
enfuvirtide (Eurogentec) concentrations (0.04 ng/ml to 156103 ng/
ml). Viral input was adjusted to produce 105 RLUs. Infection (in
triplicate wells) was synchronized by spinoculation and luciferase
activity was monitored 48 hours after infection. IC50 values were
calculated using the GraphPad Prism software and resistance was
expressed as the fold-change in IC50 (FCIC50) relative to HXB2.
Statistical analyses
RI and FCIC50 are expressed as median with the 25
th and 75th
percentiles [interquartile range, IQR] and p-values,0.05 (two-
sided) were considered statistically significant. Intra-patient results
were compared using a nonparametric Kruskal-Wallis test
followed by Dunn’s Multiple Comparison Test. Nonparametrical
Mann-Whitney test (U-test) was used to compare inter-patient
samples and Wilcoxon signed-rank test to analyze paired Env and
HR1–HR2 recombinant viruses. For dual-tropic Env recombinant
viruses, mean FCIC50s were used.
Supporting Information
Figure S1 Construction of the pNL4-3Denv.Luc and the
pNL4-3DHR1–HR2.Luc vectors. After subloning of the EcoRI-
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NotI fragment from pNL4-3.GIV.eGFP into pZero-2, fragments
6220–8322 or 7854–8214 were deleted by inverse PCR and an
AfeI and AscI restriction site was introduced in each of the
constructs respectively. The SalI-BamHI fragments deleted of the
Env ectodomain or of the HR1–HR2 regions were cloned into the
SalI-BamHI digested pNL4-3.Luc in order to generate the final
backbones pNL4-3Denv.Luc and pNL4-3DHR1–HR2.Luc.
(PDF)
Table S1 Supporting table
(PDF)
Table S2 Supporting table
(PDF)
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